Mirum Pharmaceuticals, Inc.
MIRMDrugs in Pipeline
9
Phase 3 Programs
4
Upcoming Catalysts
2
Next Catalyst
Jun 15, 2026
14wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
Blinded CDCA 250 mg TID
CTX
Maralixibat
Biliary Atresia
Cholic acid
Inborn Errors of Bile Acid Synthesis
Cholic Acids
Infantile Refsum's Disease
Volixibat
Primary Biliary Cholangitis
Ursodeoxycholic Acid
PBC
Low dose of MRM-3379
Fragile X Syndrome
LUM001 (Maralixibat)
Alagille Syndrome
LUM001
Alagille Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Blinded CDCA 250 mg TID | Phase 3 | CTX | - | - |
Maralixibat | Phase 3 | Biliary Atresia | - | - |
Cholic acid | Phase 3 | Inborn Errors of Bile Acid Synthesis | - | - |
Cholic Acids | Phase 3 | Infantile Refsum's Disease | - | - |
Volixibat | Phase 2 | Primary Biliary Cholangitis | - | - |
Ursodeoxycholic Acid | Phase 2 | PBC | - | - |
Low dose of MRM-3379 | Phase 2 | Fragile X Syndrome | - | - |
LUM001 (Maralixibat) | Phase 2 | Alagille Syndrome | - | - |
LUM001 | Phase 2 | Alagille Syndrome | - | - |
Alagille Syndrome
3 drugs in this indication
Inborn Errors of Bile Acid Synthesis
1 drug in this indication
PBC
1 drug in this indication
Fragile X Syndrome
1 drug in this indication
Biliary Atresia
1 drug in this indication
Primary Biliary Cholangitis
1 drug in this indication
CTX
1 drug in this indication
Infantile Refsum's Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)